OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
|Podcasts|June 8, 2023
Public Health Matters - Advocating for Patients, Impacting Public Health
Christina Madison speaks with Sandra Leal, PharmD, fromCVS Health, about advocating for patients and how that impacts public health.
Advertisement
On this episode, host Dr. Christina Madison speaks with Sandra Leal, PharmD, MPH, FAPhA, Vice President of pharmacy innovations for CVS Health, about advocating for patients and how that impacts public health.
Advertisement
Related to this article
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
5